Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Gastrointestinal 1

Conditions

Pancreatic Neoplasms 43Carcinoma, Non-Small-Cell Lung 35Breast Neoplasms 35Triple Negative Breast Neoplasms 16Neoplasms 15Neoplasm Metastasis 14Carcinoma 9Adenocarcinoma 9Lung Neoplasms 7Head and Neck Neoplasms 6Colorectal Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Pancreatic Diseases 5Cholangiocarcinoma 5Carcinoma, Squamous Cell 5Neoplasms by Site 4Melanoma 4Digestive System Neoplasms 4Digestive System Diseases 4Sarcoma 3Pancreatic Adenocarcinoma 3Neoplasms by Histologic Type 3Inflammatory Breast Neoplasms 3Endocrine System Diseases 3Endocrine Gland Neoplasms 3Carcinoma, Pancreatic Ductal 3Carcinoma, Ovarian Epithelial 3Uveal Melanoma 2Urinary Bladder Neoplasms 2

Interventions

Gemcitabine 47Cisplatin 32pembrolizumab 28Paclitaxel 13Docetaxel 13avelumab 12Mitomycin 12atezolizumab 11Nivolumab 11Cystectomy 10Carboplatin 9durvalumab 7Sunitinib 7apaziquone 6Doxorubicin 6BCG Vaccine 65-aminolevulinic acid hexyl ester 6Vinblastine 5Radiation 5Platinum 5Methotrexate 5Magnetic Resonance Spectroscopy 5Albumin-Bound Paclitaxel 5Taxes 4Standard of Care 4Sorafenib 4Radiotherapy 4Fluorouracil 4Erlotinib Hydrochloride 41,2-diaminocyclohexaneplatinum II citrate 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Urinary Bladder Neoplasms × 130-nm albumin-bound paclitaxel × Clear all
NCT04306900 2025-07-29

TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers

Trishula Therapeutics, Inc.

Phase 1 Completed
185 enrolled 28 charts
GastrointestinalGenitourinaryThoracic

Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

NCT02887248 2023-12-05

Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma

SCRI Development Innovations, LLC

Phase 2 Terminated
3 enrolled 9 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡